搜尋結果
2024年4月30日 · When prostate cancer spreads to other parts of the body, it's called metastatic cancer. Treatments can slow or shrink a stage 4 prostate cancer. But most stage 4 prostate cancers can't be cured.
2023年1月11日 · Although there have been many new developments in the last few years, metastatic castration resistant prostate cancer remains a deadly disease. This article provides an overview of currently approved treatment options as well as new therapies that are not standard of care yet.
- 10.3390/cancers15020461
- 2023/01
- Cancers (Basel). 2023 Jan; 15(2): 461.
2024年8月30日 · Metastatic prostate cancer is a stage of prostate cancer where the cancer cells have spread from the prostate to distant parts of the body. It is also called stage IV cancer. Does chemo...
2021年9月2日 · Recently, lutetium-177-prostate-specific membrane antigen-617 with standard of care treatment has shown to improve overall survival in men with advanced-stage prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
- Nicolas Sayegh, Umang Swami, Neeraj Agarwal
- 2021
2024年8月16日 · Metastatic prostate cancer is a type of cancer that begins in your prostate and has spread to other parts of your body. The most common place for prostate cancer to...
- The TNM method stages cancer by providing three different scores. Lower numbers generally mean less advanced cancer than higher numbers. The three...
- PSA is a protein made by your prostate. Prostate cancer cells can also make PSA. If a PSA test reveals that you have high PSA levels, it could be a...
- Metastatic prostate cancer isn't necessarily terminal. While there isn’t a known cure, it can respond to treatment and be controlled in many cases.
2018年2月7日 · Metastatic prostate cancer can be broadly divided into two groups: disease that has not been treated with androgen deprivation and disease that is resistant to such therapy. Treating metastatic...
2024年9月15日 · In this trial, conducted at sites across Europe and North America, patients with metastatic prostate cancer who had disease progression on their first-line ARPI treatment were randomly allocated to receive either 177 Lu-PSMA-617 (up to six cycles, administered
metastatic prostate cancer 相關
廣告每支含1克EPA。醫學實証連續飲用7星期，每日2克EPA及高蛋白質配方(2支)，有助增加體重，. 減輕治療副作用，維持抵抗力，按時完成療程。立即加入營養支持計劃。
